Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Change in Account Payables: 2023-2025

Historic Change in Account Payables for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Sep 2025 value amounting to $1.0 million.

  • Tonix Pharmaceuticals Holding's Change in Account Payables rose 116.06% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year increase of 220.14%. This contributed to the annual value of $927,000 for FY2024, which is 126.56% up from last year.
  • Latest data reveals that Tonix Pharmaceuticals Holding reported Change in Account Payables of $1.0 million as of Q3 2025, which was down 66.68% from $3.1 million recorded in Q2 2025.
  • Tonix Pharmaceuticals Holding's Change in Account Payables' 5-year high stood at $3.7 million during Q2 2024, with a 5-year trough of -$6.4 million in Q3 2024.
  • For the 3-year period, Tonix Pharmaceuticals Holding's Change in Account Payables averaged around $106,273, with its median value being $581,000 (2024).
  • Examining YoY changes over the last 5 years, Tonix Pharmaceuticals Holding's Change in Account Payables showed a top increase of 425.22% in 2024 and a maximum decrease of 725.07% in 2024.
  • Tonix Pharmaceuticals Holding's Change in Account Payables (Quarterly) stood at -$3.9 million in 2023, then spiked by 114.76% to $581,000 in 2024, then skyrocketed by 116.06% to $1.0 million in 2025.
  • Its Change in Account Payables stands at $1.0 million for Q3 2025, versus $3.1 million for Q2 2025 and -$353,000 for Q1 2025.